Physician profile
Noa Tal
NPI 1437619160
$8,776.11
in general payments reported to CMS, 2019-2025
12 companies · $8,549 in 2025
The $8,549 reported for 2025 was more than what 89% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $101 · 2024: $126 · 2025: $8,549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $6,073 · Food and Beverage: $1,757 · Travel and Lodging: $893 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $52.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $6,073.00 |
| Food and Beverage | $1,757.46 |
| Travel and Lodging | $892.98 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $52.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Recordati_rare_diseases_inc. | $7,581.84 | 2025 | Isturisa |
| Ascendis Pharma Endocrinology INC | $491.10 | 2025 | Yorvipath, Skytrofa |
| Novo Nordisk INC | $183.54 | 2025 | Ozempic, Sogroya |
| Madrigal Pharmaceuticals | $102.27 | 2025 | Rezdiffra |
| Corcept Therapeutics | $100.63 | 2023 | Korlym |
| Amgen INC. | $98.70 | 2025 | Evenity |
| Ascensia Diabetes Care US INC. | $91.34 | 2024 | |
| Genentech USA, INC. | $35.00 | 2024 | Ocrevus Zunovo |
| Chiesi USA, INC. | $28.67 | 2025 | Mycapssa |
| Caris Mpi, INC. | $23.89 | 2025 | Mi Cancer Seek |
| Lilly USA, LLC | $19.71 | 2025 | Zepbound |
| Springworks Therapeutics, INC. | $19.42 | 2025 | Gomekli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noa Tal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.